Agilent Technologies Inc (NYSE:A) insider Dominique Grau sold 8,902 shares of Agilent Technologies stock in a transaction that occurred on Monday, December 3rd. The shares were sold at an average price of $74.00, for a total value of $658,748.00. Following the completion of the transaction, the insider now owns 103,387 shares of the company’s stock, valued at $7,650,638. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
A opened at $71.91 on Friday. The company has a market cap of $23.24 billion, a PE ratio of 26.13, a price-to-earnings-growth ratio of 2.04 and a beta of 1.36. The company has a current ratio of 3.29, a quick ratio of 2.74 and a debt-to-equity ratio of 0.39. Agilent Technologies Inc has a twelve month low of $60.42 and a twelve month high of $75.11.
Agilent Technologies (NYSE:A) last released its quarterly earnings results on Monday, November 19th. The medical research company reported $0.81 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.74 by $0.07. The company had revenue of $1.29 billion for the quarter, compared to analysts’ expectations of $1.26 billion. Agilent Technologies had a return on equity of 19.84% and a net margin of 6.43%. The business’s revenue for the quarter was up 8.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.67 earnings per share. As a group, analysts anticipate that Agilent Technologies Inc will post 3.04 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, January 23rd. Stockholders of record on Monday, December 31st will be issued a dividend of $0.164 per share. This represents a $0.66 dividend on an annualized basis and a dividend yield of 0.91%. The ex-dividend date is Friday, December 28th. This is a boost from Agilent Technologies’s previous quarterly dividend of $0.15. Agilent Technologies’s payout ratio is 21.51%.
A number of large investors have recently made changes to their positions in A. OppenheimerFunds Inc. raised its holdings in Agilent Technologies by 64.0% during the second quarter. OppenheimerFunds Inc. now owns 7,636,621 shares of the medical research company’s stock worth $472,248,000 after purchasing an additional 2,980,216 shares in the last quarter. Marshall Wace LLP raised its holdings in Agilent Technologies by 170.0% during the third quarter. Marshall Wace LLP now owns 2,649,502 shares of the medical research company’s stock worth $186,896,000 after purchasing an additional 1,668,360 shares in the last quarter. Point72 Asset Management L.P. raised its holdings in Agilent Technologies by 1,375.4% during the third quarter. Point72 Asset Management L.P. now owns 1,504,860 shares of the medical research company’s stock worth $106,153,000 after purchasing an additional 1,402,860 shares in the last quarter. American Century Companies Inc. raised its holdings in Agilent Technologies by 30.3% during the second quarter. American Century Companies Inc. now owns 4,585,162 shares of the medical research company’s stock worth $283,546,000 after purchasing an additional 1,065,877 shares in the last quarter. Finally, Pictet Asset Management Ltd. raised its holdings in Agilent Technologies by 26.9% during the third quarter. Pictet Asset Management Ltd. now owns 2,350,857 shares of the medical research company’s stock worth $165,829,000 after purchasing an additional 498,430 shares in the last quarter.
A has been the subject of a number of research reports. Morgan Stanley lifted their target price on Agilent Technologies from $84.00 to $86.00 and gave the company an “overweight” rating in a research note on Wednesday, October 10th. Goldman Sachs Group restated a “buy” rating and issued a $82.00 target price (up from $77.00) on shares of Agilent Technologies in a research note on Tuesday, September 18th. Cleveland Research downgraded Agilent Technologies from a “buy” rating to a “neutral” rating in a research note on Monday, November 12th. ValuEngine upgraded Agilent Technologies from a “hold” rating to a “buy” rating in a research note on Thursday, September 13th. Finally, Zacks Investment Research downgraded Agilent Technologies from a “buy” rating to a “hold” rating in a research note on Tuesday, October 16th. Two analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $78.75.
TRADEMARK VIOLATION NOTICE: This article was first posted by WKRB News and is the property of of WKRB News. If you are reading this article on another publication, it was copied illegally and reposted in violation of US and international copyright laws. The original version of this article can be read at https://www.wkrb13.com/2018/12/07/insider-selling-agilent-technologies-inc-a-insider-sells-658748-00-in-stock.html.
About Agilent Technologies
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; microfluidics based automated electrophoresis products; cell analysis plate based assays; laboratory software and informatics systems; laboratory automation; dissolution testing; vacuum pumps; and measurement technologies.
See Also: What is a stock buyback?
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.